BackNeumora Therapeutics Overview
Neumora Therapeutics Inc.

Neumora Therapeutics Target Price

Analysts' average 12-month price target for Neumora Therapeutics is $5.

Get informed when a big investor buys or sells

+ Follow

Share Price

$0.47

Average Target Price

$5.00963.8% upside

1 analysts in the last 4 months

High: $5 | Low: $5

Analyst Recommendations

No recommendations in the last 4 months.

Revenue & Income Forecast

Analysts' Target Prices

DateAnalystPrice TargetCurrent Upside/Downside
2026-07-13RBC CapitalBrian Abrahams$5963.8% upsideOpen
2026-06-18Mizuho Securities$4751.1% upsideOpen
2026-01-12Leerink PartnersMarc Goodman$81602.1% upsideOpen
2026-01-05Mizuho SecuritiesGraig Suvannavejh$61176.6% upsideOpen
2025-12-01RBC Capital$71389.4% upsideOpen
2025-10-28Needham$81602.1% upsideOpen
2025-03-07Stifel Nicolaus$2325.5% upsideOpen
2025-01-02RBC CapitalBrian Abrahams$4751.1% upsideOpen
2024-07-22NeedhamAmi Fadia$234793.6% upsideOpen
2024-07-08Mizuho SecuritiesGraig Suvannavejh$204155.3% upsideOpen
2024-06-17RBC CapitalBrian Abrahams$296070.2% upsideOpen
2024-03-13RBC CapitalBrian Abrahams$316495.7% upsideOpen
2023-10-10Stifel NicolausPaul Matteis$265431.9% upsideOpen
2023-10-10RBC CapitalBrian Abrahams$245006.4% upsideOpen

Neumora Therapeutics (NMRA) FAQ

Neumora Therapeutics (NMRA) currently reports a target price of $5. Use the charts on this page to explore Neumora Therapeutics's target price history and peer comparisons.

Analysts' average 12-month price target for Neumora Therapeutics is $5, about 963.8% upside from the current share price of $0.47. That spread summarizes where covering analysts expect the stock could trade over the next year, not a guarantee. Review the individual firm targets on this page — a wide high-to-low range often means opinion is split.

Start with the current target price of $5, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Neumora Therapeutics, and consider following NMRA for alerts when major investors trade the stock.